Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results

Zogenix (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today provided a corporate update and announced financial results for the fourth quarter and year ended December 31, 2017.

As quoted in the press release:

“Following positive results from our first global Phase 3 trial, Study 1, evaluating ZX008 in Dravet syndrome, Zogenix entered 2018 in strong operating and financial positions,” said Stephen J. Farr, Ph.D., President and CEO of Zogenix. “Based on the results from Study 1, we were recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for ZX008 in Dravet syndrome. We now look forward to the availability of top-line results towards the end of the second quarter of this year from our second pivotal Phase 3 trial, Study 1504, which recently completed enrollment. Assuming a successful outcome for Study 1504, we intend to submit applications for regulatory approvals of ZX008 as adjunctive treatment for Dravet syndrome in the U.S. and Europe in the fourth quarter of 2018.”

Click here to read the full press release.